Video

Dr. Velcheti on the Importance of Real-World Data in NSCLC

Vamsidhar Velcheti, MD, discusses the importance of real-world data for patients with non–small cell lung cancer.

Vamsidhar Velcheti, MD, the director of thoracic medical oncology at NYU Langone Health Perlmutter Cancer Center, discusses the importance of real-world data for patients with non–small cell lung cancer.

A gap can sometimes exist between clinical trial data and every day clinical practice, Velcheti says. The expectation of treatments from clinical trials following their FDA approval may not necessarily reflect outcomes in the real world, he continues. 

When physicians treat patients in clinical practice, they may not be the same as the homogeneous patient population that is normally included in clinical trials. Due to this, it is important to validate clinical trial findings in a real-world setting to ensure the treatment is most applicable, Velcheti concludes.

Related Videos
Benjamin P. Levy, MD, with Kristie Kahl and Andrew Svonavec
Noman Ashraf, MD
Ivy Riano, MD, of Dartmouth Geisel School of Medicine
Daniel E. Haggstrom, MD
Daniel E. Haggstrom, MD
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss unmet needs and future research directions in ALK-positive and ROS1-positive NSCLC.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for lorlatinib in ROS1-positive NSCLC after crizotinib and chemotherapy.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for taletrectinib in ROS1-positive advanced non–small cell lung cancer.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, on progression patterns and subsequent therapies after lorlatinib in ALK-positive NSCLC.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss preclinical CNS data for the ROS1 inhibitor zidesamtinib.